Actuarial Patient Survival, Relapse, and LFS in Patients Randomized to Treatment With Busulfan or TBI
| Parameter . | Busulfan (n = 88) . | TBI (n = 79) . | P . |
|---|---|---|---|
| Survival, 7 yr (%) | |||
| All patients | 54 | 63 | .16 |
| Early disease3-150 | 72 (n = 59) | 67 (n = 61) | .6 |
| Advanced disease3-151 | 17 (n = 29) | 49 (n = 18) | .005 |
| Relapse, 7 yr (%) | |||
| All patients | 29 | 29 | |
| Early disease | 21 | 27 | |
| Advanced disease | 50 | 36 | |
| LFS, 7 yr (%) | |||
| All patients | 51 | 62 | .11 |
| Early disease | 68 | 66 | |
| Advanced disease | 17 | 49 | .009 |
| AML | 59 (n = 37) | 56 (n = 32) | .7 |
| ALL | 28 (n = 18) | 45 (n = 20) | .36 |
| CML | 56 (n = 30) | 77 (n = 26) | .13 |
| AML first remission | 80 (n = 25) | 58 (n = 26) | .24 |
| ALL first remission | 27 (n = 11) | 36 (n = 11) | .86 |
| CML first chronic phase | 72 (n = 22) | 83 (n = 24) | .42 |
| Parameter . | Busulfan (n = 88) . | TBI (n = 79) . | P . |
|---|---|---|---|
| Survival, 7 yr (%) | |||
| All patients | 54 | 63 | .16 |
| Early disease3-150 | 72 (n = 59) | 67 (n = 61) | .6 |
| Advanced disease3-151 | 17 (n = 29) | 49 (n = 18) | .005 |
| Relapse, 7 yr (%) | |||
| All patients | 29 | 29 | |
| Early disease | 21 | 27 | |
| Advanced disease | 50 | 36 | |
| LFS, 7 yr (%) | |||
| All patients | 51 | 62 | .11 |
| Early disease | 68 | 66 | |
| Advanced disease | 17 | 49 | .009 |
| AML | 59 (n = 37) | 56 (n = 32) | .7 |
| ALL | 28 (n = 18) | 45 (n = 20) | .36 |
| CML | 56 (n = 30) | 77 (n = 26) | .13 |
| AML first remission | 80 (n = 25) | 58 (n = 26) | .24 |
| ALL first remission | 27 (n = 11) | 36 (n = 11) | .86 |
| CML first chronic phase | 72 (n = 22) | 83 (n = 24) | .42 |